|
Amale Hawi Ph.D. joined Penwest in May of 2007as Senior Vice President Pharmaceutical Development. Dr. Hawi has primary responsibility for Penwest's preclinical and CMC drug development strategy and manages the pharmaceutics and pharmacokinetics groups.
Dr. Hawi has over 17 years of pharmaceutical development experience in the areas of drug discovery support product development and regulatory affairs. Before joining Penwest Dr. Hawi served as President of A. Hawi Consulting Ltd a firm she founded in 2002 which focused on biopharmaceutical concepts strategies and the development of new chemical entities for numerous pharmaceutical and biotechnology companies. Prior to that Dr. Hawi served in various roles of increasing responsibility at Boehringer Ingelheim Pharmaceuticals from 1990 culminating in her appointment to Director of Drug Metabolism and Pharmacokinetics a position she assumed in 1998. Dr. Hawi has a Ph.D. in Organic Chemistry from the University of London Queen Elizabeth College and both an M.S. and a B.S. in Chemistry from the American University of Beirut Lebanon. Dr. Hawi is a member of the American Association of Pharmaceutical Scientists (AAPS) and has published over 40 articles in academic journals and research publications | 